Lipella Pharmaceuticals Inc. announced the creation of a Scientific Advisory Board in oral health.  The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP). LP-310 is a proprietary liposomal oral rinse formulation of liposomal tacrolimus. The Board will also provide guidance on the design of the company's phase 2a multicenter dose escalation study of LP-310 for IND submission and will assist Lipella with additional indications in oral liposomal drug delivery and treatment.

Members of the advisory board include: Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board. Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL. Michael Brennan, DDS, MHS, Chairman, Department of Oral Medicine/Oral & Maxillofacial Surgery, Atrium Health Carolinas Medical Center, Charlotte, NC; Professor, Department of Otolaryngology/Head & Neck Surgery, Wake Forest University School of Medicine, Winston-Salem, NC.  Kamal Al-Eryani, DDS, PhD, Associate Professor of Orofacial Science, Chief of Oral Medicine Services, UCSF School of Dentistry, San Francisco, CA.

Vidya Sankar, DMD, MHS, Associate Professor and Division Director for Oral Medicine, Tufts University School of Dental Medicine, Boston, MA. Hervé Y. Sroussi, DMD, PhD, Associate Surgeon and Director for Research, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital and an Associate Professor in the Department of Oral Medicine, Infection and Immunity at the Harvard School of Dental Medicine, Boston, MA.